Citadel Advisors’s Elicio Therapeutics ELTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$989K Buy
+543,450
New +$1.51M ﹤0.01% 8483
2026
Q2
– Sell
-15,978
Closed -$160K – 13959
2026
Q1
$171K Buy
+15,978
New +$154K ﹤0.01% 11569
2024
Q4
– Sell
-12,856
Closed -$64.7K – 14710
2024
Q3
$64.7K Buy
+12,856
New +$57K ﹤0.01% 11635
2024
Q1
– Sell
-14,005
Closed -$117K – 14746
2023
Q4
$117K Sell
14,005
-2,201
-14% -$14.3K ﹤0.01% 10738
2023
Q3
$137K Buy
+16,206
New +$154K ﹤0.01% 10496
2022
Q4
– Sell
-1,468
Closed -$14K – 14981
2022
Q3
$14K Sell
1,468
-4,548
-76% -$47.5K ﹤0.01% 12175
2022
Q2
$69K Buy
+6,016
New +$96.1K ﹤0.01% 11713
2021
Q3
– Sell
-2,386
Closed -$311K – 13971
2021
Q2
$311K Sell
2,386
-1,110
-32% -$160K ﹤0.01% 11171
2021
Q1
$631K Buy
+3,496
New +$675K ﹤0.01% 9171

Other funds holding ELTX

Citadel Advisors's ELTX Position: Q3 2026 in Review

Citadel Advisors opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 543,450 shares worth $989K. The stake represents ﹤0.01% of the portfolio and ranks #8483 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ELTX as recently as Q1 2026.

Citadel Advisors first reported a position in ELTX in Q1 2021 and has held it in 9 quarters since. 78 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Citadel Advisors held 543,450 shares of Elicio Therapeutics worth $989K as of Q3 2026.
  • Elicio Therapeutics was a new Citadel Advisors position in Q3 2026.
  • Elicio Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #8483 holding.
  • Citadel Advisors first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • 78 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.